PENELOPE MARKHAM
CIK 1770555 · EVP Liver Cirrhosis R&D · last filed 2023-02-22
PENELOPE MARKHAM is an EVP Liver Cirrhosis R&D who has filed 3 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing shows the insider had shares withheld for taxes covering $15.2K of BIVI on Feb 22, 2023. Current disclosed insider exposure totals $636 across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$636
1
3
$0
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIVI | EVP Liver Cirrhosis R&D | 478 | $1.33 | $636 | $0 | 3 | 2023-02-22 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-02-22 | BIVI | Tax (F) | −2,476 | -$15.2K | EDGAR |
| 2023-01-18 | BIVI | Grant (A) | +39,624 | $0 | EDGAR |
| 2021-09-16 | BIVI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.